Search results for "L. Bueno. Mechanisms involved in bacterial pathogen-induced intestinal mucosal barrier disruption: Therapeutic interest of mecha"

Noventure grants Axmer exclusive distribution right for its products Oleoabrax® EHO and EPA3G® in Sweden, Denmark, Norway, Finland, Estonia, Latvia and Lithuania. Oleoabrax® EHO is a hydrogel whose patented formulation grants it the ability to promote and speed up the process of healing wounds of full and partial thickness.
European Association of Urology - London 25th - 27th March 2017. More than 10.300 total participants, coming from 113 countries all over the world. Out of around 10.000 delegates, mainly urologists, nearly 20% were residents. 200 exhibitors took part to the congress, thus adding  further 2200 participants to the event.
Noventure will attend the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN), taking place in Vienna & Online, from May 17th to 23rd, 2023
New partnership: Xilaplus® AF in Turkey Noventure is delighted to announce its new partnership with Generica İlaç to market Noventure’s Xilaplus® AF in Turkey.
Environ Microbiol. 2013 Feb;15(2):334-46.  
We are pleased to announce the launch of Rhinosectan® in its first market, Spain.
The medical device is used to restore the physiological function of the intestinal wall as well as to prevent and alleviate dysbacteriosis of different nature origin.
OLEOABRAX®  EHO is an hydrogel which contains Fucocert® (polysaccharide) and glycerine as moisturizers, as well as Olea europaea leaf extract, included because of its antioxidant properties. The presence of Carbopol 980® provides an isolating and protective barrier for the wound bed.